Introduction
============

Hepatocellular carcinoma (HCC) ranks 5^th^ (men) and 9^th^ (women) in frequency and is globally third leading cause of cancer-related death [@B1]. Although most cases of HCC occur in Africa and Eastern Asia, trends in HCC have shown considerable increases in low-incidence areas such as the United States and Canada [@B2]. Chronic hepatitis B or C virus (HBV or HCV) infections are the major risk factors for HCC [@B3]. The increasing level of diagnosis in high-risk populations, such as ultrasonography and computed tomographic scanning, has led to the identification of increasing numbers of patients with HCC. Although the survival benefit of surgical techniques and preoperative management in HCC has been well made, its prognosis remains dismal [@B4], [@B5]. Actually, serum alpha-fetoprotein (AFP) was widely recognized and utilized as a diagnostic and prognostic marker of HCC [@B6], [@B7].However, AFP was increased in 211-58% of patients with chronic hepatitis or cirrhosis without HCC, and 30-40% of HCC patients were AFP negative [@B6], [@B8], [@B9]. Moreover, AFP was also reported to have no prognostic role in small hepatocellular carcinoma patients with well-compensated cirrhosis [@B10]. Thus, identifying simple and reliable biological markers to predict patient who are at high-risk for early death and recurrence would be important.

Albumin (ALB) and globulin (GLB), the two major constituents of serum proteins, are routinely measured by biochemical examinations. Both of them are considered to play a pivotal role in the inflammatory process. Serum ALB level, as well as albumin/globulin ratio (AGR), has been known as a prognostic indicator in several types of cancer, including gastric cancer, colorectal cancer, breast cancer, ovarian cancer and nasopharyngeal carcinoma [@B11]-[@B13]. In contrast to the considerable amount of researches on ALB and AGR, however, whether the impact of the GLB and A/G ratio is associated with outcome in patients with HCC has not yet been elucidated. Therefore, the purpose of this study was to assess whether preoperative globulin and A/G ratio had a prognostic value in patients with HCC.

Methods
=======

Study population
----------------

Data involved was collected from patients suffering HCC and receiving liver resection in the First Affiliated Hospital of Nanjing Medical University (NJMU) and Nanjing Drum Tower Hospital, Nanjing, China between January 2007 and December 2012. The latest detection of serum ALB level, GLB level and albumin/globulin ratio (AGR) was recorded before liver resection operation. Patients aged between 18 and 85 years at diagnosis, undergoing partial liver resection with pathologically confirmed HCC as primary tumor were included. Patients who had preexisting diseases of immune system, received immunosuppressive therapies involving recent exposure of steroid or other immunity medicine before operation, and those died within 30 days after surgery were excluded from this study. Meanwhile, patients with incomplete clinical information including vascular invasion, tumor multiplicity, tumor size, Edmondson grade, or without follow up were excluded.

The study was approved by the Institutional Ethics Committee of the First Affiliated Hospital of NJMU. And our research was performed according to the Helsinki Declaration and government policies. Written informed consent was obtained from all patients.

Statistical analysis
--------------------

Basic information about patients, and data of clinicopathological and laboratory examination was retrieved from the medical recording system of the first affiliated hospital of NJMU. Patients\' clinical features including sex, age, level of HbsAg, ALT (U/L), AFP (ng/ml), GLB (g/L), ALB (g/L), cirrhosis or not, pathological features about vascular invasion, tumor multiplicity, tumor size, Edmondson grade and information on follow up was obtained. Serum level of GLB, ALB as well as HbsAg, ALT and AFP was detected by an automatic biochemical analyzer (Hitachi 7600). All the patients were further divided into two groups based on criterion as follows: (1) sex: male or female; (2) age: ≤ 60 years (young group) or \>60 years (old group); (3) serum HbsAg: negative (normal) or positive (abnormal); (4) ALT level: ≤ 45 U/L (normal) or \>45 U/L (abnormal); (5) AFP level: ≤ 13.6 U/L (normal) or \>13.6 U/L (abnormal); (6) cirrhosis in liver tissues: absent or present; (7) tumor vascular invasion: absent or present; (8) tumor multiplicity: solitary or multiple; (9) tumor size: ≤ 5 cm or \>5 cm; (10) Edmondson grade: Ⅰ-Ⅱ or Ⅲ-Ⅳ. The AGR value was calculated, \[AGR = Albumin/(Total protein - Albumin)\]. The cutoff value was selected by X-title program and set as follows: GLB, 32.70 g/L; ALB, 40.60 g/L; AGR, 1.40. CSS, calculated from the date of diagnosis to the date of cancer specific death was selected as the primary endpoint of the study. Deaths were set as events and deaths attributed to other causes were set as censored observation. Kaplan-Meier estimates were applied to graph the survival curves, and log-rank test was performed to analyze the differences between the curves. Risk factors for survival outcomes in HCC patients were analyzed using Multivariable Cox regression models. Chi-square test was performed for categorical variables. 5-year CSS was evaluated from Kaplan-Meier curves. SPSS 17.0 for Windows (IBM Corp, Armonk, NY, USA) was used to perform all the statistical analyses. P \< 0.05 (two-tailed test) was considered statistical significant.

Results
=======

Patients
--------

210 patients in total initially diagnosed as HCC and receiving liver resection in the first affiliated hospital of NJMU from 2007 to 2012 were involved in this study as a training cohort (Table [1](#T1){ref-type="table"}). Among them, 173 are male (82.4%) and 37 (17.6) are female. The average age of the patients was 55 years (range, 47-75 years). Of these 184 (87.6%) were chronic hepatitis B patients, and 160 (76.2%) were diagnosed as liver cirrhosis. During follow-up, 107 patients experienced HCC recurrence and 75 patients developed tumor metastasis. By the end of follow-up, 153/210 patients (72.9%) died of HCC.

Identification of optimal cut-off value for GLB, ALB, and AGR
-------------------------------------------------------------

The mean value of GLB and ALB involved were 29.88 g/L (range, 18.30-41.40 g/L) and 37.71 g/L (range, 18.40- 51.70 g/L), respectively. And the mean value of AGR involved was 1.30 (range, 0.70-2.30). X-tile program was applied to set the optimal cut-off points for GLB, ALB and AGR. The GLB cutoff value for CSS was 32.70 g/L with maximum χ2 log-rank value of 10.625 (P= 0.001), and all patients were divided into either high (\>32.70 g/L) or low (≤32.70 g/L) GLB groups. Similarly, an ALB cutoff point of 40.60 g/L and an AGR cutoff point of 1.40 were selected as the optimal cutoff value for survival analyses (χ2 = 10.038, P = 0.002, and χ2 = 13.172, P \< 0.001, respectively) to divide the patients involved into low and high risk subsets in terms of CSS (Figure. 1).

Association of ALB and GLB with the clinicopathological features of HCC
-----------------------------------------------------------------------

On the basis of the optimal cutoff value, 138/210 patients (65.7 %) had a low ALB level and 149/210 patients (71.0 %) had a low GLB level. When stratified by the test results of serum level of AFP and pathological results of cirrhosis, tumor size and Edmondson grade, the patient distribution of the GLB level differed significantly. Comparing with patients in higher GLB group (12/61, 19.7%), more patients were with low AFP level in the low GLB group (67/149, 43.0%) (P=0.001). Conversely, significantly more patients had basic liver cirrhosis in high GLB group (52/61, 85.2 %) than in low GLB group (108/149, 72.5 %) (P=0.049). Moreover, there were higher percentage of patients with tumor size of ≤5 in the low GLB (104/149, 69.8%) group than patients in higher GLB group (21/61, 34.4%) (P=0.001). More patients were classified as Edmondson grade I-II in high GLB group (29/122, 23.8 %) than in low GLB group (7/64, 10.9 %) (P=0.025).

The patient distribution of ALB level showed significant difference when stratified by the test results of HbsAg, ALT, AFP and pathological results of cirrhosis and Edmondson grade. Significantly more patients were with low HbsAg level in the high ALB group (24/72, 33.3%) than in the low ALB group (2/138, 1.4%) (P\<0.001). More patients were in high level of ALT in the high ALB group (61/72, 84.7%) than in the low ALB group (98/138, 71.0%) (P=0.028). And there were higher percentage of patients with a higher serum value of AFP in the high ALB group (43/72, 59.7%) than in the low ALB group (36/138, 26.1%) (P\<0.001). In addition, comparing with patients in low ALB group (25/138, 18.1%), more patients had basic liver cirrhosis in the high ALB group (25/72, 34.7%) (P=0.007). More patients were classified as Edmondson grade I-II in high ALB group (56/72, 77.8%) than in low ALB group (62/138, 44.9%) (P\<0.001) (Table [2](#T2){ref-type="table"}).

Prognostic value of ALB, GLB, and AGR
-------------------------------------

As the results of univariate analysis indicated, the high serum of AFP (P=0.005) and GLB (P=0.001), low serum level of ALB (P=0.002), low AGR value (P\<0.001) and other clinicopathological factors involving tumor vascular invasion (P=0.012), tumor multiplicity (P=0.001), tumor size (P\<0.001) and Edmondson grade (P\<0.001) were significant risk factors for poor survival of HCC patients suffering liver resection (Table [3](#T3){ref-type="table"}).

Various prognostic factors were adjusted with the performance of multivariate Cox regression analysis. In accordance with the results of univariate analysis, the high serum level of GLB (hazard ratio \[HR\] 1.865; 95 % confidence interval \[CI\] 1.089-3.194, P= 0.023), low serum level of ALB (HR 0.658; 95 % CI 0.436-0.993, P=0.046), tumor vascular invasion (HR 1.847; 95 % CI 1.221-2.795, P=0.004), tumor multiplicity (HR 0.361; 95 % CI 0.230-0.567, P\<0.001), tumor size (HR 2.308; 95 % CI 1.588-3.354, P\<0.001) and Edmondson grade (HR 2.784; 95 % CI 1.694-4.573, P\<0.001) were suggested as independent predictive factors for HCC. A serum value of higher GLB and low ALB demonstrated a negative effect on CSS. However, the serum level of AFP and AGR score were not significant predictive factors in multivariate analysis (Table [3](#T3){ref-type="table"}).

Validation of the prognostic value of GLB
-----------------------------------------

To verify the prognostic value of GLB in HCC patients, we recruited validation cohort involving 100 HCC patients from the other cohort. Clinical information of patients was listed in Table. S1. According the cut-off we identified in Figure [1](#F1){ref-type="fig"}, patients were divided into two groups. As expected, high serum level of GLB (hazard ratio \[HR\] 1.376; 95 % confidence interval \[CI\] 1.049-2.795, P= 0.032), low serum level of ALB (HR 0.622; 95 % CI 0.439-0.972, P=0.039) were associated with poor outcome of HCC (Figure [2](#F2){ref-type="fig"} and Table [S2](#SM0){ref-type="supplementary-material"}).

Discussion
==========

As a kind of malignant tumor with high morbidity and motility, HCC is always characterized by delayed diagnosis and poor prognosis.[@B14] Treatments for HCC include open surgical operation, radiotherapy, radiofrequency ablation and chemotherapy.[@B15]-[@B17] For HCC patients at early stages without distant metastasis, surgical resection is the best choice.[@B18], [@B19] The reported five-year cancer specific survival (CSS) for HCC patients receiving liver resection is about 20\~40 %, which is far from satisfactory. [@B20] The prognosis of HCC may be decided by many factors, such as age, gender, tumor size, tumor stage, vascular invasion, tumor multiplicity and so forth. [@B21], [@B22] These factors may act as predicators for the prognosis of patients after HCC resection. However, sole factor is not sufficient to make an accurate prediction, as many host and tumor related factors must be considered.

Globulin, including the gamma globulins or antibodies and glycoprotein, is one the most important groups of blood proteins. [@B23] GLB may act as a regulator in the circulatory system by assisting the blood in clotting, transporting proteins through the lipoproteins, indicating antibody levels, and so forth. High globulin levels may be attributed to chronic inflammatory diseases such as chronic viral or bacterial infection, liver disease, auto-immune status, ulcerative colitis, kidney disease and so on. [@B24]-[@B28] Chronic inflammation is a common cause of multiple tumors. HCC is an inflammation related carcinoma and mounting evidence suggested that persistent chronic inflammation status is associated with poor prognosis of HCC patients. [@B29]-[@B31] Inflammation based prognostic factors involving serum C-reactive protein and the neutrophils to lymphocyte ratio have been demonstrated as potential predictors of the CSS of liver cancer. [@B32]-[@B34]

ALB is produced in the liver and forms about 50% of all plasma protein. Its main function is to regulate the colloidal osmotic pressure of blood thus maintain the volume of whole blood. It also serves as carriers for molecules of low water solubility, such as bile salts, unconjugated bilirubin, free fatty acids and so forth. Low albumin may be caused by liver disease, nephrotic syndrome, malnutrition and malignancy. [@B35]-[@B37] ALB is also suggested as a potential predictor of the CSS of liver cancer. [@B37]

Our study found that serum GLB and ALB level were promising predictors of CSS in patients treated with HCC resection. We firstly found that high GLB level was significantly related to high AFP value, the existence of cirrhosis, major tumor size and high Edmondson grade and low ALB value was markedly associated with positive HbsAg, high ALT and AFP level, the existence of cirrhosis, and high Edmondson grade. Then with the application of univariate analysis, GLB, ALB and AGR was suggested to be related to 5-year CSS, however after adjustment for AFP value, and the clinical characteristics with multivariate analysis, only the predicative GLB and ALB remained significant. An absolute improvement of 7.1% in 5-year CSS if ≤ 32.70 g/L GLB level comparing to \> 32.70 g/L (P\<0.05). And there was a 17.6% improvement in 5-year CSS if \>40.6 g/L ALB level rather than ≤ 40.6 g/L (P\<0.05). As the completed mechanisms shared by cancers and inflammation, markers of inflammatory reaction may serve as indicators of cancer diagnosis and predictors of prognosis, nevertheless, the significance of the markers was ignored to a great extent and few such markers were identified. The present study, for the first time, utilized two different cohorts to identify and confirm the cut-off of GLB and ALB, then focused on the association of serum GLB and ALB level with prognosis as well as clinicopathological parameters in HCC treated with liver section.

As a matter of fact, there exist some limitations in this study, of which, the major one would be that relevant measurements of several specific cytokines and C-reactive protein levels were missing, so consequently, we could not analyze the relationship among GLB, ALB with such inflammatory factors. Besides, this research was performed with relatively small sample, which may cause some small sample bias and limit the statistical power. Future large-scale studies involving more people with prospective designs are urgently desired.

Despite these limitations, our informative study is the first to identify the preoperative high GLB level as a prognostic risk factor for patients after curative liver resection. Furthermore, we also demonstrated ALB as an independent predictor for the prognosis according to our study population. Serum GLB and ALB value, moreover, can be obtained directly from routine medical laboratories, thus can act as available clinical biomarkers to predict the prognosis of HCC undergoing liver section.
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![**X-tile analysis of survival data of HCC patients.** X-tile analysis was done on patient data from our center, equally divided into training and validation sets. X-tile plots of the training sets are shown in the *left panels*, with plots of matched validation sets shown in the *smaller inset*. The optimal cut-point highlighted by the *black circle* in the *left panels* is shown on a histogram of the entire cohort (*middle panels*), and a Kaplan-Meier plot (*right panels*). *P* values were determined using the cutoff point defined in the training set and applying it to the validation set. A: Shows the optimal cutoff point for the GLB (32.70, χ2 = 10.625, P = 0.001). B: Shows the optimal cutoff point for the ALB (40.60, χ2 = 10.038, P = 0.002). C: Shows the optimal cutoff point for the AGR (1.40, χ2 = 13.172, P \< 0.001).](jcav10p3494g001){#F1}

![Kaplan-Meier analysis of CSS for ALB, GLB and AGR in the validation cohort. A: ALB B: GLB C: AGR.](jcav10p3494g002){#F2}

###### 

Clinical features of patients with HCC in the training cohort

                       n=210       \%
  -------------------- ----------- -------
  Age (year)           55(47-75)   
  Sex                              
  male                 173         82.4%
  female               37          17.6%
  HbsAg                            
  negative             26          12.4%
  positive             184         87.6%
  ALT (U/L)                        
  ≤45                  159         75.7%
  \>45                 51          24.3%
  AFP (ng/ml)                      
  ≤13.6                79          37.6%
  \>13.6               131         62.4%
  Cirrhosis                        
  absent               50          23.8%
  present              160         76.2%
  Vascular invasion                
  absent               52          24.8%
  present              158         75.2%
  Tumor multiplicity               
  solitary             157         74.8%
  multiple             53          25.2%
  Tumor size (cm)                  
  ≤5                   125         59.5%
  \>5                  85          40.5%
  Edmondson grade                  
  I-II                 118         56.2%
  III-IV               92          43.8%

###### 

Association among GLB, ALB and the clinical features in HCC patients.

  Variable             GLB level(g/L)   P    ALB level(g/L)   P          
  -------------------- ---------------- ---- ---------------- ----- ---- -------
  Sex                                        0.617                       0.100
  Male                 124              49                    118   55   
  Female               25               12                    20    17   
  Age                                        0.812                       0.614
  ≤60                  110              46                    101   55   
  \>60                 39               15                    37    17   
  HbsAg                                      0.799                       0.000
  negative             19               7                     2     24   
  positive             130              54                    136   48   
  ALT (U/L)                                  0.948                       0.028
  ≤45                  113              46                    98    61   
  \>45                 36               15                    40    11   
  AFP (ng/ml)                                0.001                       0.000
  ≤13.6                67               12                    36    43   
  \>13.6               82               49                    102   29   
  Cirrhosis                                  0.049                       0.007
  absent               41               9                     25    25   
  present              108              52                    113   47   
  Vascular invasion                          0.148                       0.954
  absent               41               11                    34    18   
  present              108              50                    104   54   
  Tumor multiplicity                         0.107                       0.782
  solitary             116              41                    104   53   
  multiple             33               20                    34    19   
  Tumor size (mm)                            0.000                       0.526
  ≤5                   104              45                    80    45   
  \>5                  21               40                    58    27   
  Edmondson grade                            0.000                       0.000
  I-II                 109              9                     62    56   
  III-IV               31               61                    76    16   

###### 

Univariate and multivariate survival analyses evaluating GLB, ALB, and AGR influencing CSS in HCC of the training cohort.

                               Univariate analysis   Multivariate analysis                         
  -------------------- ------- --------------------- ----------------------- --------------------- -------
  Sex                          0.463                 0.496                                         NI
  Male                 26.5%                                                                       
  Female               29.1%                                                                       
  Age                          0.059                 0.808                                         NI
  ≤60                  26.6%                                                                       
  \>60                 27.4%                                                                       
  HbsAg                        0.027                 0.870                                         NI
  negative             28.8%                                                                       
  positive             28.0%                                                                       
  ALT (U/L)                    0.873                 0.350                                         NI
  ≤45                  28.2%                                                                       
  \>45                 22.1%                                                                       
  AFP (ng/ml)                  7.727                 0.005                                         0.288
  ≤13.6                36.5%                                                 Reference             
  \>13.6               20.7%                                                 1.221 (0.845-1.764)   
  Cirrhosis                    3.400                 0.065                                         NI
  absent               30.5%                                                                       
  present              25.9%                                                                       
  Vascular invasion            6.255                 0.012                                         0.004
  absent               27.6%                                                 Reference             
  present              25.1%                                                 1.847 (1.221-2.795)   
  Tumor multiplicity           11.811                0.001                                         0.000
  solitary             18.2%                                                 Reference             
  multiple             46.2%                                                 0.361 (0.230-0.567)   
  Tumor size (mm)              34.515                0.000                                         0.000
  ≤ 5                  34.7%                                                 Reference             
  \> 5                 14.5%                                                 2.308 (1.588-3.354)   
  Edmondson grade              27.857                0.000                                         0.000
  I-II                 36.6%                                                 Reference             
  III-IV               11.4%                                                 2.784 (1.694-4.573)   
  GLB (g/L)                    10.625                0.001                                         0.023
  ≤ 32.7               31.3%                                                 Reference             
  \> 32.7              14.2%                                                 1.865 (1.089-3.194)   
  ALB (g/L)                    10.038                0.002                                         0.046
  ≤ 40.6               20.1%                                                 Reference             
  \> 40.6              37.7%                                                 0.658 (0.436-0.993)   
  AGR                          13.172                0.000                                         0.358
  ≤ 1.4                20.7%                                                 Reference             
  \> 1.4               39.4%                                                 0.811 (0.519-1.267)   

NI: not included in multivariate survival analysis. HR: hazard ratio, CI: confidence interval, GLB: globulin, ALB: albumin, AGR: albumin/globulin ratio.
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